A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19
Stopped The study will no longer move forward due to recent changes in COVID-19 cases in Hong Kong.
Conditions
Interventions
- DRUG: BRII-196 and BRII-198
- DRUG: Placebo
Sponsor
Brii Biosciences, Inc.